Vistagen Therapeutics (VTGN) Research & Development (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Research & Development of $13.1 million for Q1 2026, down 8.18% sequentially from $14.2 million in Q4 2025, and up 27.95% YoY from $10.2 million in Q1 2025.
Vistagen Therapeutics (VTGN) Research & Development (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Research & Development for 16 years, with the latest figure at $13.1 million in Q1 2026.
- Quarterly Research & Development rose 27.95% year-over-year to $13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.9 million (up 39.37% YoY) and the FY2026 annual result came in at $55.0 million, up 39.62% from the prior year.
- Research & Development slipped to $13.1 million in Q1 2026 per VTGN's latest filing, from $14.2 million in the prior quarter.
- Over five years, Research & Development peaked at $15.9 million in Q3 2025 and troughed at $3.9 million in Q3 2023.
- A 5-year average of $10.1 million and a median of $10.2 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2023: Research & Development soared 180.16% in 2022, then tumbled 72.55% in 2023.
- Over 5 years, Research & Development stood at $6.9 million in 2022, then tumbled by 33.81% to $4.5 million in 2023, then jumped by 149.17% to $11.3 million in 2024, then climbed by 25.81% to $14.2 million in 2025, then declined by 8.18% to $13.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $13.1 million, $14.2 million, and $15.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Vistagen Therapeutics | 10.35 Mn | 10.35 Mn | - | 10.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.06 Mn |
| Dec 31, 2025 | 14.22 Mn |
| Sep 30, 2025 | 15.92 Mn |
| Jun 30, 2025 | 11.68 Mn |
| Mar 31, 2025 | 10.21 Mn |
| Dec 31, 2024 | 11.31 Mn |
| Sep 30, 2024 | 10.22 Mn |
| Jun 30, 2024 | 7.65 Mn |
| Mar 31, 2024 | 7.44 Mn |
| Dec 31, 2023 | 4.54 Mn |
| Sep 30, 2023 | 3.85 Mn |
| Jun 30, 2023 | 4.20 Mn |
| Mar 31, 2023 | 9.34 Mn |
| Dec 31, 2022 | 6.85 Mn |
| Sep 30, 2022 | 12.89 Mn |
| Jun 30, 2022 | 15.29 Mn |
| Mar 31, 2022 | 12.23 Mn |
| Dec 31, 2021 | 7.78 Mn |
| Sep 30, 2021 | 9.94 Mn |
| Jun 30, 2021 | 5.46 Mn |